MX2016013913A - Compuesto heterociclico biciclico o triciclico novedoso. - Google Patents

Compuesto heterociclico biciclico o triciclico novedoso.

Info

Publication number
MX2016013913A
MX2016013913A MX2016013913A MX2016013913A MX2016013913A MX 2016013913 A MX2016013913 A MX 2016013913A MX 2016013913 A MX2016013913 A MX 2016013913A MX 2016013913 A MX2016013913 A MX 2016013913A MX 2016013913 A MX2016013913 A MX 2016013913A
Authority
MX
Mexico
Prior art keywords
heterocyclic compound
atom
tricyclic heterocyclic
novel bicyclic
nitrogen atom
Prior art date
Application number
MX2016013913A
Other languages
English (en)
Inventor
Hideki Horiuchi
Kenji Fukunaga
Okuyama Masahiro
Norimitsu Hayashi
Usui Kenji
Iijima Daisuke
Itagaki Noriaki
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54332502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016013913(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2016013913A publication Critical patent/MX2016013913A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto heterocíclico bicíclico o tricíclico novedoso representado por la fórmula (I) (ver Fórmula) en donde el anillo A es un grupo aromático opcionalmente sustituido, uno de X1 y X2 es un átomo de carbono, y el otro es un átomo de nitrógeno, X3 es un átomo de nitrógeno, o CR2, X4 es un átomo de nitrógeno, o CR3, X5 es un átomo de azufre, o -CH=CH-, Z1 es un átomo de oxígeno, -C(R6)(R7)-, -NH-, -C(R6)(R7)-NH-, -NH-C(R6)(R7)-, -C(R6)(R7)-O-, -O-C(R6)(R7)-, o un enlace sencillo, uno de Z2 y Z3 es CH y el otro es un átomo de nitrógeno, o ambos son átomos de nitrógeno, y otros símbolos son tal como se definen en la DESCRIPCIÓN, o una sal farmacológicamente aceptable del mismo.
MX2016013913A 2014-04-23 2015-04-22 Compuesto heterociclico biciclico o triciclico novedoso. MX2016013913A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014089185 2014-04-23
PCT/JP2015/062165 WO2015163339A1 (ja) 2014-04-23 2015-04-22 新規二環性または三環性複素環化合物

Publications (1)

Publication Number Publication Date
MX2016013913A true MX2016013913A (es) 2016-11-15

Family

ID=54332502

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013913A MX2016013913A (es) 2014-04-23 2015-04-22 Compuesto heterociclico biciclico o triciclico novedoso.

Country Status (13)

Country Link
US (1) US10065972B2 (es)
EP (2) EP3135674A4 (es)
JP (1) JP6442485B2 (es)
KR (1) KR102458990B1 (es)
CN (1) CN106661017B (es)
AU (1) AU2015251207B2 (es)
BR (1) BR112016024455B1 (es)
CA (1) CA2946702C (es)
MX (1) MX2016013913A (es)
PH (1) PH12016502091A1 (es)
RU (1) RU2702113C2 (es)
TW (1) TWI693227B (es)
WO (1) WO2015163339A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6853782B2 (ja) * 2015-10-22 2021-03-31 田辺三菱製薬株式会社 新規二環性複素環化合物
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
JP7254246B2 (ja) 2019-11-25 2023-04-07 アムジエン・インコーポレーテツド デルタ－５デサチュラーゼ阻害剤としての複素環式化合物及び使用方法
TW202330552A (zh) * 2021-10-13 2023-08-01 美商雷密克斯醫療公司 調節剪接之化合物及方法
CN114315760A (zh) * 2021-12-29 2022-04-12 内蒙古久日新材料有限公司 一种2-氯-1-（4-吗啉苯基）-1-丁酮的制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519055A (en) 1993-08-06 1996-05-21 University Of Maryland At Baltimore Substituted kynurenines and process for their preparation
GB9716101D0 (en) * 1997-07-30 1997-10-01 Pharmacia & Upjohn Spa Fused heterocyclic compounds
JP2010518080A (ja) * 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
CA2763960C (en) * 2009-06-18 2014-07-08 Pfizer Inc. Bicyclic and tricyclic compounds as kat ii inhibitors
AU2011336217B2 (en) * 2010-12-01 2015-10-01 Pfizer Inc. KAT II inhibitors
KR101544290B1 (ko) * 2010-12-01 2015-08-12 화이자 인코포레이티드 Kat ii 억제제
CA2874400A1 (en) 2012-06-15 2013-12-19 Pfizer Inc. Tricyclic compounds as kat ii inhibitors

Also Published As

Publication number Publication date
JPWO2015163339A1 (ja) 2017-04-20
KR20160144025A (ko) 2016-12-15
KR102458990B1 (ko) 2022-10-25
TWI693227B (zh) 2020-05-11
PH12016502091B1 (en) 2017-01-09
RU2016145602A (ru) 2018-05-23
US10065972B2 (en) 2018-09-04
AU2015251207B2 (en) 2019-08-22
EP3683222A1 (en) 2020-07-22
CA2946702A1 (en) 2015-10-29
EP3135674A4 (en) 2017-12-20
CA2946702C (en) 2022-06-28
RU2702113C2 (ru) 2019-10-04
EP3683222B1 (en) 2021-10-06
BR112016024455B1 (pt) 2023-02-07
PH12016502091A1 (en) 2017-01-09
TW201602115A (zh) 2016-01-16
BR112016024455A2 (pt) 2017-08-15
JP6442485B2 (ja) 2018-12-19
CN106661017A (zh) 2017-05-10
EP3135674A1 (en) 2017-03-01
CN106661017B (zh) 2019-09-24
AU2015251207A1 (en) 2016-12-08
RU2016145602A3 (es) 2018-11-14
WO2015163339A1 (ja) 2015-10-29
US20160376289A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
PH12016502091A1 (en) Novel bicyclic or tricyclic heterocyclic compound
PH12019550041A1 (en) Compounds and methods for ido and tdo modulation, and indications therefor
CL2019002032A1 (es) Procesos para preparar un inhibidor de jak1 (divisional de solicitud 1790-2018).
MX2018000048A (es) Inhibidores de hpk1 y métodos de uso de los mismos.
TW201613872A (en) IRAK4 inhibiting agents
PH12015501934B1 (en) New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors
MD20140135A2 (ro) Inhibitori macrociclici ai viruşilor din familia Flaviviridae
MX2016011992A (es) Derivados de piperidina-diona.
CO6650360A2 (es) Derivados de imidazopiridina, su procedimiento de preparació;n y su aplicación en terapéutica
NZ724503A (en) Macrocyclic inhibitors of flaviviridae viruses
CO6561783A2 (es) Inhibidores del virus flaviviridae
MA40171A (fr) Dérivés d'azamophinan et leur utilisation
MX2015011436A (es) Triazolopiridinas sustituidas y metodos para usarlas.
MX348726B (es) Inhibición del il17 e ifn-gamma para el tratamiento de inflamación autoinmune.
MX353762B (es) Inhibicion de il17 e ifn-gamma para el tratamiento de inflamacion autoinmune.
MA39956A (fr) Analogues du benzomorphane et leur utilisation
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
WO2013149001A3 (en) Novel fused naphthalene cyclohetero ring compounds, and methods and uses thereof
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
MX340574B (es) Imidazo pirazinas.
PH12016501751A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
JOP20200030A1 (ar) مركب خماسي الحلقة
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
JOP20190163B1 (ar) منشط nrf2
WO2014150513A3 (en) A polyoxazoline chelating agent